Kalaris Therapeutics, Inc.

Market Cap

$117M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$4.44-$3.86 (-46.51%)

Jun 5, 2026

52W High $10.9852W Low $2.27

Company Details

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth fact...

CEO

—

IPO Date

Jul 30, 2020

Website

kalaristx.com

Key Metrics TTM

Revenue

- YoY

Net Income

-$44M

EPS (Diluted)

Free Cash Flow

-$49M

Revenue / Share

$0.00

Gross Margin

Operating Margin

Net Margin

FCF Margin

P/S

P/E

Earnings Reports

Q1 2026

May 12, 2026

FY 2025

Mar 17, 2026

Q4 2025

Mar 17, 2026

Q3 2025

Nov 12, 2025

Q2 2025

Aug 13, 2025

Revenue & Profitability

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee